1. 2003 First Half-Year Result July, 2003 - 1 UCB Group 29 th July, 2003 2003 First Half-Year Result Georges Jacobs Chairman of the Executive Committee

2. 2003 First Half-Year Result July, 2003 - 2 Sectorial Breakdown UCB Group Total Turnover1,3251,512+14%+ 25% Pharma780739 Surface Specialties 545773 - of which Films 202186 H1 2002 H1 2003 Exceptional-3 -31 Taxation -81 -61 Net Profit after Taxation 182136-25% Total Ordinary Profit266228 -14% 0% Pharma242193 Surface Specialties2031 - of which Films -10- Non sectorial 44 (in EUR million) At constant exchange rate In €

3. 2003 First Half-Year Result July, 2003 - 3 UCB Pharma Turnover 780739818 H1-2002 H1-2003 (in EUR million) Pharma Allergy Neurology Others 51 % 30 % 19 % At constant exchange rate

4. 2003 First Half-Year Result July, 2003 - 4 UCB Pharma Ordinary profit242 193230 H1-2002 H1-2003 (in EUR million) Pharma Decrease Zyrtec turnover in Europe Unfavourable net exchange variances amounting to € 37 million Compensation of the cancellation of the Ditropan XL agreement (€ 23 million) booked during first half of 2002 At constant exchange rate

5. 2003 First Half-Year Result July, 2003 - 5 First Half-Year 2003 Allergy Franchise Global In-Market Turnover: EUR 860 million (*) USA582 574 + 21% Europe212 180 - 15 % Japan 84 79 + 6% R. of W. 30 28 - 8 % Total incl. licencees 908 860 - 5 % H1-2002 H1-2003 (in EUR million) Pharma USA: Sharp increase despite decrease of overall Rx market EUROPE: Zyrtec decreases due to generic competition while Xyzal more than doubled its turnover JAPAN: Market share has decreased from 17% to 15% in local currency Pfizer royalties 72 71 + 21% (*) UCB consolidated turnover in Allergy is € 374 million (USA: € 127 million; EU: € 146 million; Japan: € 73 million; ROW: € 28 million) In €

6. 2003 First Half-Year Result July, 2003 - 6 Keppra Turnover First Half-Year 2003: EUR 135 million USA 66 90 +66% Europe 28 45 +61% R. of W. 0.81- Total Turnover95135 +43% H1-2002 H1-2003 (in EUR million) Keppra is the first choice in add-on therapy among new AEDs in the US Most succesful launch in key markets vs. existing new AEDs Pharma in local currency In €

7. 2003 First Half-Year Result July, 2003 - 7 Research & Development ucb 34714 Keppra® CNS: ucb 35440 Efletirizine Xyzal® Allergy/Asthma: In progress Completed IIIIIIFiling Multiple compounds in preclinical stage Line extension: Paediatric, Primary Generalized Seizures, Monotherapy New Indications: Exploratory Trials New Formulations: oral solution, IV Allergic Asthma and inflammatory respiratory diseases Acute pain, Neuro-degenerative diseases, Epilepsy related disorders IV Pharma Pre-Clinical

8. 2003 First Half-Year Result July, 2003 - 8 Total turnover negatively affected by € 67 million due to dollar depreciation Acquired Solutia activities amounted to € 262 million in turnover Volumes remain good but pressure on margins Films break-even Surface Specialties Turnover545 773840 - of which Films202186208 Ordinary profit 203133 - of which Films-10-- H1-2002 H1- 2003 (in EUR million) Coating Resins & Additives Films & Adhesives Technical Resins 32 % 59 % 9 % At constant exchange rate

9. 2003 First Half-Year Result July, 2003 - 9 Outlook and Challenges for 2003 Pharma Confidence for Zyrtec in the US Increase Xyzal sales in Europe Increase sales and marketing for Zyrtec in Japan Optimize R&D efforts Reap benefits of business development Surface Specialties Integrate the new structure Benefit from first synergies UCB Group

10. 2003 First Half-Year Result July, 2003 - 10 UCB Group 29 th July, 2003 2003 First Half-Year Result Georges Jacobs Chairman of the Executive Committee